These guidelines, presented at the latest international EASL congress, include the most recent evidence and recommendations for the diagnosis and treatment of two liver diseases: autoimmune hepatitis and hepatitis B.
Personalised diagnosis and treatment of autoimmune hepatitis
Autoimmune hepatitis is a chronic inflammatory liver disease of immunological origin that can affect people of any age and sex. While there is no cure, immunosuppressive therapy has significantly improved the prognosis in recent decades. Dr. Maria Carlota Londoño contributed to the development of the EASL guideline.
The document highlights the clinical variability of the disease, from asymptomatic cases to severe acute forms, and stresses the importance of accurate diagnosis based on a combination of laboratory tests, autoantibody detection, and liver biopsy. The guideline summarises the latest evidence on immunosuppressive treatment and provides guidance for management in adults, children, and special populations, as well as recommendations for monitoring complications and long-term follow-up.
Strategies for the control and elimination of hepatitis B
Hepatitis B is a chronic viral infection affecting more than 250 million people worldwide and is a leading cause of cirrhosis and liver cancer. Dr. Sabela Lens has been a co-author of the new EASL guideline, which incorporates the latest knowledge in diagnosis, treatment, and prevention.
The updated EASL guideline on hepatitis B offers comprehensive recommendations for the diagnosis, treatment, and prevention of this viral infection, which remains a global public health challenge. The guideline emphasises early diagnosis, risk stratification, and personalised antiviral therapy, as well as the importance of vaccination and screening to advance towards disease elimination. It also addresses the use of simplified algorithms to facilitate management in resource-limited settings and includes recommendations for special populations and the prevention of viral reactivation.
These guidelines reinforce the role of Clínic-IDIBAPS professionals in international research and clinical practice, helping to improve the care and prognosis of people with liver diseases.
Guideline references:
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025 May 8:S0168-8278(25)00174-6. doi: 10.1016/j.jhep.2025.03.018.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025 May 10:S0168-8278(25)00173-4. doi: 10.1016/j.jhep.2025.03.017.
